Fundraising FoxCardurion Pharmaceuticals, Inc.
Burlington, US · Founded 2017 · Delaware corporation · 5 known investors
Find your way into Cardurion Pharmaceuticals, Inc.
Sign up to see every warm intro you have to Cardurion Pharmaceuticals, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cardurion Pharmaceuticals, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
MM
Michael MendelsohnNamed on SEC filing
Board
ER
Evan RachlinBoard director
PL
Peter LawrenceBoard director
EM
Edward MathersBoard directorGeneral Partner at NEA Secondary
AK
ND
JK
DL
Daniel LynchBoard director
ER
Emma ReeveBoard director
Investors · 5
Bain Capital Life Scienceslisted by Bain Capital Life SciencesBostonvia Adam M. Koppel · board
How we know: Bain Capital Life Sciences's portfolio page · board seat on SEC Form D · press coverage · Not right? Tell us
Bain CapitalreportedBoston
How we know: funding news · Not right? Tell us
Bain Capital Tech OpportunitiesreportedBoston
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$431.7M disclosed across 5 rounds · 2017–2024
▶$260.4MraisedJul 2024 · 19 investors · BiotechnologyRule 506(b)
▶$260.4MraisedJul 2024 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Evan RachlinDirector
- Jeb KeiperDirector
- Michael MendelsohnExecutive Officer, Director
- Daniel LynchDirector
- Emma ReeveDirector
- Peter LawrenceExecutive Officer, Director
- Edward MathersDirector
- Adam KoppelDirector
- Nicholas DowningDirector
- Offering amount
- $260.4M
- Amount sold
- $260.4M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$128.1MraisedJul 2023 · 2 investors · BiotechnologyRule 506(b)
▶$128.1MraisedJul 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adam KoppelDirector
- Keith GottesdienerDirector
- Kenneth NovackDirector
- Jeb KeiperDirector
- Nicholas DowningDirector
- Michael MendelsohnExecutive Officer, Director
- Peter LawrenceExecutive Officer, Director
- Offering amount
- $128.1M
- Amount sold
- $128.1M
- Finders' fees
- $3.1M
- Placement agents
- SVB Leerink LLC
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17.5MraisedDec 2022 · 2 investors · BiotechnologyRule 506(b)
▶$17.5MraisedDec 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adam KoppelDirector
- Kenneth NovackDirector
- Amy SchulmanDirector
- Peter LawrenceExecutive Officer, Director
- Nicholas DowningDirector
- Jeb KeiperDirector
- Michael MendelsohnExecutive Officer, Director
- Keith GottesdienerDirector
- Offering amount
- $17.5M
- Amount sold
- $17.5M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$10MraisedNov 2019 · 2 investors · BiotechnologyRule 506(b)
▶$10MraisedNov 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeb KeiperDirector
- Amy SchulmanDirector
- Kenneth NovackDirector
- Michael MendelsohnExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$15.7MraisedApr 2017 · 1 investors · BiotechnologyRule 506(b)
▶$15.7MraisedApr 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael MendelsohnExecutive Officer, Director
- Offering amount
- $22.4M
- Amount sold
- $15.7M
- First sale
- Mar 2017
- Incorporated
- Limited Liability Company, Georgia, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Cardurion Pharmaceuticals, Inc.'s investors?
- Cardurion Pharmaceuticals, Inc.'s investors include Bain Capital Life Sciences, Bain Capital, Bain Capital Tech Opportunities, Polaris Partners, Third Rock Ventures.
- How much funding has Cardurion Pharmaceuticals, Inc. raised?
- Cardurion Pharmaceuticals, Inc. has disclosed $431.7M raised across 5 rounds.
- Where is Cardurion Pharmaceuticals, Inc. headquartered?
- Cardurion Pharmaceuticals, Inc. is headquartered in Burlington, US.